JDRF and its affiliates celebrate Teplizumab approval
TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds the decision from the U.S Food and Drug Administration (FDA) to approve Provention Bio's teplizumab. Teplizumab is …